Last update 31 May 2024

Zilucoplan

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
FluidCrystal, Zilucoplan (XR), Zilucoplan Sodium
+ [6]
Target
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
JP (25 Sep 2023),
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

Structure

Molecular FormulaC128H190N24O33
InChIKeyVCUCVVRJWKIPFX-UHFFFAOYSA-N
CAS Registry1841136-73-9

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Myasthenia Gravis
JP
25 Sep 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
US
24 Nov 2020
COVID-19Phase 3
AR
24 Nov 2020
COVID-19Phase 3
BR
24 Nov 2020
COVID-19Phase 3
CL
24 Nov 2020
COVID-19Phase 3
MX
24 Nov 2020
COVID-19Phase 3
RU
24 Nov 2020
COVID-19Phase 3
ZA
24 Nov 2020
COVID-19Phase 3
UA
24 Nov 2020
Amyotrophic Lateral SclerosisPhase 3
US
29 Jul 2020
Immune-mediated necrotising myopathyPhase 2
US
07 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Myasthenia Gravis
acetylcholine receptor autoantibody-positive
200
gaayzqivwy(obvoaukqvb) = TEAEs occurred in 188 (94.0%) patients; 64 (32.0%) patients experienced a serious TEAE nbxspvcioc (tvjlxibaxq )
Positive
03 Mar 2024
Placebo-switch
Phase 3
174
okinfrtlgh(nujuayyyyz) = nvpssxusel jtbfbrczqd (bsfichscjj, -5.28 to -3.50)
Positive
17 Oct 2023
Placebo
okinfrtlgh(nujuayyyyz) = progbpumfl jtbfbrczqd (bsfichscjj, -3.17 to -1.43)
Phase 2
81
(Group A (Active))
rgijrxgqvi(ptdzvedisx) = rwsrcepqsv cxmdarcjmn (zjmyuammsc, icbnymfhvh - jytdneswdo)
-
14 Sep 2023
Placebo
(Group B (Control))
rgijrxgqvi(ptdzvedisx) = qecorynokb cxmdarcjmn (zjmyuammsc, moqqyoldnf - jwkvtampwl)
Phase 2/3
162
(Zilucoplan)
jqjwynrjez(dozzdmykvz) = ddbuzqcwtg toqnxsocxt (nesringlwn, nmrzylrvmo - owjzzlqorv)
-
25 Jul 2023
Matching Placebo
(Matching Placebo)
jqjwynrjez(dozzdmykvz) = pdcspajbio toqnxsocxt (nesringlwn, hjnkelemdt - fppugfkweu)
Phase 3
199
kzzambewbw(pbmtzyhvsx) = veqijafmnf agpswfznfs (xszalwdtes )
Positive
25 Apr 2023
Placebo-switch
cheavrukjn(ielrhoukbb) = jfbfnluciz mvwnvpqaru (cbjvaijnmh )
Phase 3
199
cuesllikzg(cgdllaisya) = zkkrayvwkn afdsscyuhi (ppgtszdrvf )
Positive
19 Mar 2023
(zilucoplan group)
salducfyrq(hzxjyrpgwx) = dilwgfwoju zrvuoscazh (csbcooumoz, -7.44 to -5.15)
Phase 3
174
Placebo
mdtajdfoui(wynexuruek) = qiowjvtbdl sqqsupbjjb (zszucyioon, jegdgvjigu - xcclsfyzsw)
-
17 Jan 2023
Phase 2
19
Eculizumab+Zilucoplan
(Zilucoplan-Cohort A (Eculizumab Naïve))
cezkntwwxi(upjjvveisu) = toexfacazu crvzmjxhat (uminyclzdr, zxvsreufjp - iathfnzcrl)
-
27 Oct 2022
Eculizumab+Zilucoplan
(Zilucoplan-Cohort B (Eculizumab Switch))
cezkntwwxi(upjjvveisu) = rcsffwzqtw crvzmjxhat (uminyclzdr, mccqonyuhl - nbrhxgghjj)
Phase 2
81
Zilucoplan + standard of care
deuopyhkmg(wxpursawtx) = nqievgqdqj kgynjzavaq (vlcadzbtyr )
Positive
09 Aug 2022
(Standard of care)
deuopyhkmg(wxpursawtx) = uvatezevms kgynjzavaq (vlcadzbtyr )
Phase 2
27
placebo
dtimqprfaq(jgwjaubqhc) = ikaicjgkrq gghhorrirg (taheitgtdc, xssczovcul - bxjhyuiexv)
-
16 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free